Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database
Older myeloma patients given triple-drug combination therapy lived significantly longer, challenging assumptions that elderly patients need gentler treatment.
This large NCDB retrospective study demonstrates that older MM patients (≥70) receiving combined C+H+I within 30 days achieve median OS of 64.2 months — significantly higher than mono/dual regimens — yet this combination is underutilized, particularly in the oldest age groups. The findings challenge age-based treatment restrictions and support individualized care plans accounting for functional status in elderly MM patients.
What the study was
- Study design
- Retrospective cohort study (NCDB 2004-2021)
- Population
- Multiple myeloma patients ≥70 years in the US National Cancer Database, 2004-2021
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Current Problems in Cancer
Why it surfaced
Clinically relevant finding highlighting underutilization of effective intensive MM regimens in elderly patients (≥70), a population that makes up the majority of MM diagnoses. NCDB data (2004-2021) provides robust historical patterns. The HR=0.575 for C+H+I is a strong survival signal supporting practice change in this age group.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.